Qualification of Hemophilia Treatment Centers to Enable Multi-Center Studies of Gene Expression Signatures in Blood Cells from Pediatric Patients

Hemophilia A is a rare congenital bleeding disorder caused by a deficiency of functionally active coagulation factor VIII (FVIII). Most patients with the severe form of the disease require FVIII replacement therapies, which are often associated with the development of neutralizing antibodies against...

Descripción completa

Detalles Bibliográficos
Autores principales: Reipert, Birgit M., Hofbauer, Christoph J., Gangadharan, Bagirath, Berg, Verena, Donnachie, Elizabeth, Meeks, Shannon, Mancuso, Maria Elisa, Bowen, Joel, Brown, Deborah L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10004246/
https://www.ncbi.nlm.nih.gov/pubmed/36902866
http://dx.doi.org/10.3390/jcm12052080

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10004246/
https://www.ncbi.nlm.nih.gov/pubmed/36902866
http://dx.doi.org/10.3390/jcm12052080

Ejemplares similares